Newsroom
Sorted by: Latest
-
Generis Group Named One of Canada’s Top Growing Companies 2026 by The Globe and Mail
TORONTO--(BUSINESS WIRE)--Generis Group is pleased to announce it has ranked #157 on the 2026 Report on Business magazine ranking of Canada’s Top Growing Companies, marking the fifth time the company has earned a place on The Globe and Mail’s annual ranking. Generis also ranked #6 in the Marketing category. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Generis earned its spot with three-year revenue growth of 167% from 2022 to 2025. “We’re incredibly prou...
-
ASTRO 2026 Presentations Demonstrate Role of Genetics in Predicting Adverse Events and Response From Radiation Treatment
LOS ANGELES--(BUSINESS WIRE)--ASTRO 2026 presentations demonstrate role of genetics in predicting adverse events and response from radiation treatment....
-
New Data Highlight Artera's MMAI Consistency Across Diverse Patient Populations at ASTRO 2026
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will be featured in new data presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. Collectively, these studies expand the evidence supporting MMAI's potential to deliver consistent, biologically meaningful insights across diverse patient populations and clinical settings. The findings carry implications for more personal...
-
NetApp kündigt geplante Übernahme von PEAK:AIO zur Weiterentwicklung einer skalierbaren KI-Infrastrukturarchitektur an
SAN JOSE, Kalifornien, USA--(BUSINESS WIRE)--NetApp® (NASDAQ: NTAP), das Unternehmen für intelligente Dateninfrastruktur, hat heute die geplante Übernahme von PEAK:AIO bekannt gegeben. PEAK:AIO ist ein Pionier für Metadatenarchitekturen der nächsten Generation und hochleistungsfähige parallele Dateisysteme. Mit der geplanten Übernahme will NetApp die Entwicklung seiner KI-Infrastruktur beschleunigen. Dazu sollen die Metadatendienste ausgebaut und neue Funktionen für parallele Namensräume integr...
-
Advocacy Unveils Promptless, Revolutionizing AI Litigation Platform by Putting Humans in Control
SAN FRANCISCO--(BUSINESS WIRE)--Advocacy, the first context-driven AI platform for litigation, today released Promptless, a major expansion of its matter-centric technology that delivers AI support to litigation teams proactively—without prompting—while also giving a new level of primacy to human judgment in an AI litigation platform. Built on Advocacy’s existing document review, drafting, and collaboration features, Promptless eliminates the need for litigators to start AI-assisted work with a...
-
Securities Fraud Investigation Into Tigo Energy, Inc. (TYGO) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Tigo Energy, Inc. (“Tigo” or the “Company”) (NASDAQ: TYGO) investors concerning the Company’s possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON TIGO ENERGY, INC. (TYGO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happened?On August 4,...
-
NYSE to Commence Delisting Proceedings Against SilverBox Corp IV (SBXD)
NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange LLC (“NYSE” or “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the three securities enumerated below (“Securities”) of SilverBox Corp IV (the “Company”) from the NYSE. Trading in the Company’s Securities will be suspended immediately. Symbol Description SBXD Class A ordinary shares, par value $0.0001 per share SBXDU Units, each consisting of one Class A ordinary share, $0.0001 p...
-
Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
RAHWAY, N.J.--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy has been voluntarily withdrawn. The decision to withdraw the BLA is based on discussions wit...
-
MVB Bank Announces Strategic Partnership With DingoBlu Financial
FAIRMONT, W.Va.--(BUSINESS WIRE)--DingoBlu Financial, Inc., a financial technology company developing a mobile-first platform for personal financial products, today announced a strategic partnership with MVB Bank, Inc. The partnership represents an important milestone as DingoBlu prepares to introduce its platform and suite of financial products.DingoBlu is a Visa fintech partner, and its debit card program will run on the Visa network through its bank partner, MVB Bank. Through the relationship...
-
The New York Times Company Declares Regular Quarterly Dividend
NEW YORK--(BUSINESS WIRE)--The New York Times Company’s Board of Directors today declared a regular quarterly dividend of $0.23 per share on the Company’s Class A and Class B common stock. The dividend is payable on October 22, 2026, to shareholders of record as of the close of business on October 7, 2026. The New York Times Company (NYSE: NYT) is a trusted source of quality, independent journalism whose mission is to seek the truth and help people understand the world. With more than 13 millio...